The Pennine Acute Hospitals
NHS Trust Formulary
 
back
6 Endocrine system
06-01-02-03 GLP-1 receptor mimetics

GLP-1 mimetics should only be considered as third-line therapy in accordance with NICE NG28).

 

GLP-1 mimetics should only be continued if reduction of at least 1% point in HbA1c AND a weight loss of at least 3% of initial body weight at 6 months


Liraglutide Victoza®
First Choice
Disposable pen

Green 1 View adult BNF  View SPC online  View childrens BNF
Semaglutide Ozempic®
First Choice

Disposable pen


StarOnce-weekly preparationStar


Green 1 View adult BNF  View SPC online  View childrens BNF
Exenatide Bydureon® prolonged-release
Formulary

Disposable pen

StarOnce-weekly preparationStar


Green 1 View adult BNF  View SPC online  View childrens BNF
Lixisenatide Lyxumia®
Formulary
Disposable pen

Green 1 View adult BNF  View SPC online  View childrens BNF
Dulaglutide Trulicity®
Formulary

Disposable pen

StarOnce-weekly preparationStar


Green 1 View adult BNF  View SPC online  View childrens BNF
Exenatide Byetta®
Non Formulary

Disposable pen


Green 1 View adult BNF  View SPC online  View childrens BNF